News stories about Teva Pharmaceutical Industries (NYSE:TEVA) have been trending somewhat negative this week, according to InfoTrie. The research firm scores the sentiment of press coverage by analyzing more than 6,000 news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Teva Pharmaceutical Industries earned a coverage optimism score of -1.09 on their scale. InfoTrie also gave news stories about the company an news buzz score of 10 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have impacted Teva Pharmaceutical Industries’ analysis:
- Tinnitus Drug Market is Touching New Levels| Torrent Pharmaceuticals Ltd, AA Pharma Inc, GlaxoSmithKline plc, Sound Pharmaceuticals (marketwatch.com)
- Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $11.00 at Bank of America (americanbankingnews.com)
- Pharmaceutical Contract Manufacturing Market – Big Changes to Have Big Impact (marketwatch.com)
- Leaner, More Agile Teva Has Brighter Days Ahead (finance.yahoo.com)
- Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Increased to $16.00 by Analysts at Oppenheimer (americanbankingnews.com)
Shares of Teva Pharmaceutical Industries stock opened at $12.57 on Friday. Teva Pharmaceutical Industries has a 1 year low of $6.07 and a 1 year high of $18.14. The company has a debt-to-equity ratio of 1.62, a current ratio of 0.89 and a quick ratio of 0.56. The business has a 50 day moving average price of $10.37 and a 200 day moving average price of $8.73. The company has a market capitalization of $13.49 billion, a P/E ratio of -3.25, a P/E/G ratio of 1.24 and a beta of 1.84.
Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 15.41% and a negative net margin of 22.88%. The company had revenue of $4.47 billion during the quarter, compared to the consensus estimate of $4.35 billion. During the same quarter last year, the business posted $0.53 earnings per share. Teva Pharmaceutical Industries’s revenue was up 1.1% compared to the same quarter last year. As a group, research analysts expect that Teva Pharmaceutical Industries will post 2.27 EPS for the current fiscal year.
A number of research analysts recently commented on TEVA shares. SunTrust Banks increased their price target on shares of Teva Pharmaceutical Industries from $9.00 to $13.00 and gave the company a “hold” rating in a report on Thursday. ValuEngine cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, December 3rd. Oppenheimer upped their price objective on Teva Pharmaceutical Industries from $12.00 to $16.00 and gave the company an “outperform” rating in a research report on Thursday. Cfra raised their price objective on Teva Pharmaceutical Industries from $11.00 to $13.00 and gave the company a “hold” rating in a research note on Wednesday. Finally, Wells Fargo & Co lifted their target price on Teva Pharmaceutical Industries from $8.00 to $10.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 22nd. Four equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and seven have assigned a buy rating to the company. Teva Pharmaceutical Industries has a consensus rating of “Hold” and an average target price of $11.38.
In other news, VP Hafrun Fridriksdottir sold 4,310 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.49, for a total value of $45,211.90. Following the completion of the sale, the vice president now owns 24,883 shares of the company’s stock, valued at $261,022.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP David Matthew Stark sold 12,538 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $12.24, for a total value of $153,465.12. Following the completion of the sale, the vice president now owns 15,512 shares of the company’s stock, valued at approximately $189,866.88. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 21,647 shares of company stock valued at $257,561. 0.49% of the stock is owned by insiders.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Recommended Story: 52- Week Highs
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.